An Open-Label, Randomized, Crossover Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Perampanel (Primary) ; Perampanel (Primary)
- Indications Epilepsy; Partial epilepsies; Seizures; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 01 Jul 2022 Results published in the Clinical Pharmacology in Drug Development
- 08 Dec 2020 Results of pooled analysis from ctp:250913 and 291633 presented at the 74th Annual Meeting of the American Epilepsy Society
- 06 Sep 2018 Status changed from recruiting to completed.